Role of anti-inflammatory cytokines IL-4 and IL-13 in systemic sclerosis

Inflammation Research

Volumn 64, Issue 3-4, 2015, Pages 151-159

  Huang, Xiao Lei ^a   Wang, Yu Jie ^a   Yan, Jun Wei ^a   Wan, Ya Nan ^a   Chen, Bing ^a   Li, Bao Zhu ^a   Yang, Guo Jun ^b   Wang, Jing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Fibrosis; IL 13; IL 4; Inflammation; Systemic sclerosis; Therapy

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 4;

FIBROSIS; HOMEOSTASIS; HUMAN; INFLAMMATION; MEDLINE; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; SYSTEMIC SCLEROSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION;

FIBROSIS; HUMANS; INFLAMMATION; INTERLEUKIN-13; INTERLEUKIN-4; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION;

EID: 84925501437     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-015-0806-0     Document Type: Review

References (81)

1. Naraghi K, van Laar JM. Update on stem cell transplantation for systemic sclerosis: recent trial results. Curr Rheumatol Rep. 2013;15(5):326.
2. Varga J, Abraham D. Systemic sclerosis: a prototype multisystem fibrotic disorder. J Clin Invest. 2007;117(3):557–67.
3. Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol. 2012;24(2):165–70.
4. Fett N. Scleroderma nomenclature, etiology, pathogenesis, prognosis, and treatments facts and controversies. Clin Dermatol. 2013;31(4):432–7.
5. Parel Y, Aurrand-Lions M, Scheja A, et al. Presence of CD4+CD8+double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum. 2007;56(10):3459–67.
6. Muangchan C, Pope JE. Interleukin 6 in systemic sclerosis and potential implications for targeted therapy. J Rheumatol. 2012;39(6):1120–4.
7. Salim PH, Jobim M, Bredemeier M, et al. Interleukin-10 gene promoter and NFKB1 promoter insertion/deletion polymorphisms in systemic sclerosis. Scand J Immunol. 2013;77(2):162–8.
8. Fuschiotti P. Role of IL-13 in systemic sclerosis. Cytokine. 2011;56(3):544–9.
9. Truchetet ME, Brembilla NC, Montanari E, et al. Interleukin-17A+cells are increased in systemic sclerosis skin and their number is inversely correlated to the extent of skin involvement. Arthritis Rheum. 2013;. doi:10.1002/art.37860.
10. Pehlivan Y, Onat AM, Ceylan N, et al. Serum leptin, resistin and TNF-α levels in patients with systemic sclerosis: the role of adipokines in scleroderma. Int J Rheum Dis. 2012;15(4):374–9.
11. Giordano N, Papakostas P, Pecetti G, et al. Cytokine modulation by endothelin-1 and possible therapeutic implications in systemic sclerosis. J Biol Regul Homeost Agents. 2011;25(4):487–92.
12. Chomarat P, Banchereau J. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int Rev Immunol. 1998;17(1–4):1–52.
13. Yao X, Zha W, Song W, et al. Coordinated regulation of IL-4 and IL-13 expression in human T cells: 3C analysis for DNA looping. Biochem Biophys Res Commun. 2012;417(3):996–1001.
14. Paul WE, Zhu J. How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol. 2010;10(4):225–35.
15. Liang HE, Reinhardt RL, Bando JK, et al. Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity. Nat Immunol. 2011;13(1):58–66.
16. Gallo E, Katzman S, Villarino AV. IL-13-producing Th1 and Th17 cells characterize adaptive responses to both self and foreign antigens. Eur J Immunol. 2012;42(9):2322–8.
17. Wills-Karp M, Finkelman FD. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal. 2008;1(51):pe55
18. Tabata Y, Khurana Hershey GK. IL-13 receptor isoforms: breaking through the complexity. Curr Allergy Asthma Rep. 2007;7(5):338–45.
19. Wijesundara DK, Tscharke DC, Jackson RJ, et al. Reduced interleukin-4 receptor α expression on CD8 + T cells correlates with higher quality anti-viral immunity. PLoS One. 2013;8(1):e55788.
20. Lacy ER. Equilibrium and kinetic analysis of human interleukin-13 and IL-13 receptor alpha-2 complex formation. J Mol Recognit. 2012;25(3):184–91.
21. Ryan JJ, McReynolds LJ, Keegan A, et al. Growth and gene expression are predominantly controlled by distinct regions of the human IL-4 receptor. Immunity. 1996;4:123–32.
22. Hershey GK. IL-13 receptors and signaling pathways: an evolving web. Allergy Clin Immunol. 2003;4(111):677–90.
23. Kelly-Welch AE, Hanson EM, Boothby MR, et al. Interleukin-4 and interleukin-13 signaling connections maps. Science. 2003;300(5625):1527–8.
24. Sun XJ, Wang LM, Zhang Y, et al. Role of IRS-2 in insulin and cytokine signaling. Nature. 1995;377:173–7.
25. White MF. The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Recent Prog Horm Res. 1998;53:119–38.
26. Bhattacharjee A, Shukla M, Yakubenko VP, et al. IL-4 and IL-13 employ discrete signaling pathways for target gene expression in alternatively activated monocytes/macrophages. Free Radic Biol Med. 2013;54:1–16.
27. Junttila IS, Mizukami K, Dickensheets H, et al. Tuning sensitivity to IL-4 and IL-13: differential expression of IL-4Rα, IL-13Rα1, and γc regulates relative cytokine sensitivity. J Exp Med. 2008;205(11):2595–608.
28. Andrews AL, Nordgren IK, Campbell-Harding G, et al. The association of the cytoplasmic domains of interleukin-4 receptor alpha and interleukin-13 receptor alpha 2 regulates interleukin-4 signaling. Mol BioSyst. 2013;9(12):3009–14.
29. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004;4:583–94.
30. Kanellakis P, Ditiatkovski M, Kostolias G, Bobik A. A pro-fibrotic role for interleukin-4 in cardiac pressure overload. Cardiovasc Res. 2012;95(1):77–85.
31. Huaux F, Liu T, McGarry B, Ullenbruch M, Phan SH. Dual roles of IL-4 in lung injury and fibrosis. J Immunol. 2003;170(4):2083–92.
32. Saito A, Okazaki H, Sugawara I, Yamamoto K. Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. Int Arch Allergy Immunol. 2003;132(2):168–76.
33. Sugimoto R, Enjoji M, Nakamuta M, Ohta S. Effect of IL-4 and IL-13 on collagen production in cultured LI90 human hepatic stellate cells. Liver Int. 2005;25(2):420–8.
34. Sommer M, Eismann U, Gerth J, Stein G. Interleukin 4 co-stimulates the PDGF-BB and bFGF-mediated proliferation of mesangial cells and myofibroblasts. Nephron. 2002;92:868–80.
35. Sempowski GD, Beckmann MP, Derdak S, Phipps RP. Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. J Immunol. 1994;152:3606–14.
36. Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest. 1992;90:1479–85.
37. Aoudjehane L, Pissaia A Jr, Scatton O, Podevin P, Massault PP, Chouzenoux S, et al. Interleukin-4 induces the activation and collagen production of cultured human intrahepatic fibroblasts via the stat-6 pathway. Lab Invest. 2008;88:973–85.
38. McGaha TL, Le M, Kodera T, Stoica C. Molecular mechanisms of interleukin-4-induced up-regulation of type I collagen gene expression in murine fibroblasts. Arthritis Rheum. 2003;48(8):2275–84.
39. Wynes MW, Riches DW. Induction of macrophage insulin-like growth factor-I expression by the Th2 cytokines IL-4 and IL-13. J Immunol. 2003;171(7):3550–9.
40. Wynes MW, Franke SK, Riches DW. IL-4-induced macrophage-derived IGF-I protects myofibroblasts from apoptosis following growth factor withdrawal. J Leukoc Biol. 2004;76(5):1019–27.
41. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N, et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of Th2 inflammation. Science. 2011;332:1284–8.
42. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32:593–604.
43. Prokop S, Heppner FL, Goebel HH, Stenzel W. M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis. Am J Pathol. 2011;178:1279–86.
44. Bellini A, Marini MA, Bianchetti L, Barczyk M, Schmidt M, Mattoli S. Interleukin (IL)-4, IL-13, and IL-17A differentially affect the profibrotic and proinflammatory functions of fibrocytes from asthmatic patients. Mucosal Immunol. 2012;5(2):140–9.
45. Zhou Y, Hagood JS, Murphy-Ullrich JE. Thy-1 expression regulates the ability of rat lung fibroblasts to activate transforming growth factor-beta in response to fibrogenic stimuli. Am J Pathol. 2004;165:659–69.
46. Firszt R, Francisco D, Church TD, Thomas JM. Interleukin-13 induces collagen type-1 expression through matrix metalloproteinase-2 and transforming growth factor-β1 in airway fibroblasts in asthma. Eur Respir J. 2014;43(2):464–73.
47. Sugimoto R, Enjoji M, Nakamuta M, Ohta S. Effect of IL-4 and IL-13 on collagen production in cultured LI90 human hepatic stellate cells. Liver Int. 2005;25(2):420–8.
48. Ingram JL, Rice A, Geisenhoffer K, Madtes DK. Interleukin-13 stimulates the proliferation of lung myofibroblasts via a signal transducer and activator of transcription-6-dependent mechanism: a possible mechanism for the development of airway fibrosis in asthma. Chest. 2003;123(3 Suppl):422S–4S.
49. Lu J, Zhu Y, Feng W, Pan Y. Platelet-derived growth factor mediates interleukin-13-induced collagen I production in mouse airway fibroblasts. J Biosci. 2014;39(4):693–700.
50. Lee CG, Homer RJ, Zhu Z, Lanone S. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta (1). J Exp Med. 2001;194(6):809–21.
51. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12(1):99–106.
52. Kaviratne M, Hesse M, Leusink M, Cheever AW. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol. 2004;173(6):4020–9.
53. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol. 1997;24(2):328–32.
54. Salmon-Ehr V, Serpier H, Nawrocki B, Gillery P, Clavel C, Kalis B, Birembaut P, Maquart FX. Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch Dermatol. 1996;132(7):802–6.
55. Distler JH, Jüngel A, Caretto D, et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum. 2006;54(1):214–25.
56. Ong C, Wong C, Roberts CR, Teh HS, Jirik FR. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol. 1998;28(9):2619–29.
57. Binai N, O’Reilly S, Griffiths B, et al. Differentiation potential of CD4 + monocytes into myofibroblasts in patients with systemic sclerosis. PLoS One. 2012;7(3):e33508.
58. Lee KS, Ro YJ, Ryoo YW, Kwon HJ, Song JY. Regulation of interleukin-4 on collagen gene expression by systemic sclerosis fibroblasts in culture. J Dermatol Sci. 1996;12(2):110–7.
59. Greenblatt MB, Aliprantis AO. The immune pathogenesis of scleroderma: context is everything. Curr Rheumatol Rep. 2013;15(1):297.
60. Riccieri V, Rinaldi T, Spadaro A, Scrivo R, Ceccarelli F, Franco MD, Taccari E, Valesini G. Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities. Clin Rheumatol. 2003;22(2):102–6.
61. Hasegawa M, Sato S, Nagaoka T, Fujimoto M, Takehara K. Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology. 2003;207(2):141–7.
62. Christmann RB, Hayes E, Pendergrass S, Padilla C, Farina G, Affandi AJ, Whitfield ML, Farber HW, Lafyatis R. Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Rheum. 2011;63(6):1718–28.
63. Fuschiotti P, Medsger TA, Morel PA. Effector CD8+T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum. 2009;60(4):1119–28.
64. Medsger TA Jr, Ivanco DE, Kardava L, et al. GATA-3 upregulation in CD8+T cells is a biomarker of immune dysfunction in systemic sclerosis, resulting in excess IL-13 production. Arthritis Rheum. 2011;63(6):1738–47.
65. Broen JC, Dieude P, Vonk MC, et al. Polymorphisms in the interleukin 4, interleukin 13, and corresponding receptor genes are not associated with systemic sclerosis and do not influence gene expression. J Rheumatol. 2012;39(1):112–8.
66. Granel B, Chevillard C, Allanore Y, et al. Evaluation of interleukin 13 polymorphisms in systemic sclerosis. Immunogenetics. 2006;58:693–9.
67. Granel B, Allanore Y, Chevillard C, et al. IL13RA2 gene polymorphisms are associated with systemic sclerosis. J Rheumatol. 2006;33:2015–9.
68. O’Garra Anne, Arai Naoko. The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol. 2000;10(12):542–50.
69. Lombardelli L, Aguerre-Girr M, Logiodice F, et al. HLA-G5 induces IL-4 secretion critical for successful pregnancy through differential expression of ILT2 receptor on decidual CD4+T cells and macrophages. J Immunol. 2013;191(7):3651–62.
70. Kuroda Etsushi, Antignano Frann, Ho Victor W, et al. SHIP represses Th2 skewing by inhibiting IL-4 production from basophils. J Immunol. 2011;186:323–32.
71. Cannons JL, Wu JZ, Gomez-Rodriguez J, et al. Biochemical and genetic evidence for a SAP-PKC-θ interaction contributing to IL-4 regulation. J Immunol. 2010;185:2819–27.
72. Bruhn S, Katzenellenbogen M, Gustafsson M, et al. Combining gene expression microarray- and cluster analysis with sequence-based predictions to identify regulators of IL-13 in allergy. Cytokine. 2012;60(3):736–40.
73. Kumar Manish, Ahmad Tanveer, Sharma Amit, et al. Let-7 microRNA-mediated regulation of IL-13 and allergic airway inflammation. J Allergy Clin Immun. 2011;128(5):1077–85.
74. Elo LL, Järvenpää H, Tuomela S, et al. Genome-wide profiling of interleukin-4 and STAT6 transcription factor regulation of human Th2 cell programming. Immunity. 2010;32(6):852–62.
75. Zhou M, Ouyang W. The function role of GATA-3 in Th1 and Th2 Differentiation. Immunol Res. 2003;28:25–37.
76. O’Reilly S, Hügle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology. 2012;51:1540–9.
77. Divekar AA, Khanna D, Abtin F, Maranian P, Saggar R, Saggar R, Furst DE, Singh RR. Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis. Clin Immunol. 2011;141(3):293–303.
78. Lightwood D, O’Dowd V, Carrington B, et al. The discovery, engineering and characterisation of a highly potent anti-human IL-13 fab fragment designed for administration by inhalation. J Mol Biol. 2013;425(3):577–93.
79. Greenblatt MB, Sargent JL, Farina G, et al. Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets. Am J Pathol. 2012;180(3):1080–94.
80. Brown M, Postlethwaite AE, Myers LK, et al. Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts. Clin Rheumatol. 2012;31(6):973–81.
81. Christmann RB, Mathes A, Affandi AJ, et al. TSLP upregulation in human SSc skin and induction of overlapping profibrotic genes and intracelullar signaling with IL-13 and TGFβ. Arthritis Rheum. 2013; doi: 10.1002